A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
NCT05443724
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
700
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
CVL-231 30 mg
Sponsor
AbbVie